Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 4,116 Shares

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 4,116 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $181,392.12. Following the transaction, the chief accounting officer owned 74,041 shares in the company, valued at $3,262,986.87. This trade represents a 5.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

Shares of Tempus AI stock traded up $0.61 during trading on Thursday, hitting $46.49. 3,802,434 shares of the stock traded hands, compared to its average volume of 5,629,236. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The stock has a market cap of $8.35 billion, a price-to-earnings ratio of -27.03 and a beta of 3.99. The firm’s fifty day moving average is $49.11 and its 200-day moving average is $59.69. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company’s revenue was up 36.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.24) EPS. Research analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Tempus AI by 8.7% in the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after buying an additional 817,014 shares during the last quarter. ARK Investment Management LLC increased its position in shares of Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares during the period. GC Wealth Management RIA LLC bought a new position in Tempus AI in the fourth quarter worth about $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its stake in Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares during the period. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Jefferies Financial Group assumed coverage on Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Robert W. Baird assumed coverage on Tempus AI in a research report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Wednesday, March 11th. Finally, BTIG Research reduced their price target on Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.